Home
About
Publications Trends
Recent Publications
Expert Search
Archive
direct kras inhibitors
What Are Some Examples of Direct KRAS Inhibitors?
Some notable direct KRAS inhibitors include
Sotorasib
(AMG 510) and
Adagrasib
(MRTX849). These drugs have shown promising results in clinical trials, particularly for patients with KRAS G12C mutations.
Frequently asked queries:
What is KRAS?
Why Target KRAS?
What Are Direct KRAS Inhibitors?
How Do Direct KRAS Inhibitors Work?
What Are Some Examples of Direct KRAS Inhibitors?
What Are the Benefits of Direct KRAS Inhibitors?
How Do In Vitro Studies Contribute to Personalized Medicine?
What Are Inclusion and Exclusion Criteria?
What is the Relationship Between ECOG Performance Status and Prognosis?
What is the Role of Nutrition in Integrative Cancer Care?
How Does EUS Work?
How Can Patients and Caregivers Access ON DPG Resources?
How Are Processed Meats Linked to Cancer?
What Are the Treatment Options for Poor Circulation in Cancer Patients?
What are Hematologic Effects in the Context of Cancer?
Why is Enteral Nutrition Important in Cancer Patients?
What is DNA Damage Response (DDR)?
Who Can Benefit from Proton Beam Therapy?
What Can Be Done to Mitigate Costs?
What are the potential solutions to data access limitations?
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Lung Cancer
Nanotechnology
Non-Hodgkin’s Lymphoma
Radiation-Induced Malignancies
Follow Us
Facebook
Linkedin
Youtube
Instagram
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
Carcinogenesis
cell adhesion
cell migration
chemotherapy
Chromatin remodeling genes
Chronic inflammation
CIAbimatoprost
Co-morbidity
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
Diagnosis challenges
diffuse large B-cell lymphoma
DNA damage
docetaxel-cyclophosphamide
Drug delivery
epirubicin-cyclophosphamide
extracellular matrix
Fibrosis
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunosuppression
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
intensity-modulated radiation therapy
Keratinocyte
Lipid-based nanoparticles
liver cancer
long-term cancer risks
Lung cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
MRI
Multi-modal Imaging
Multidisciplinary care
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
Probabilistic Models
proton therapy
Radiation-induced malignancies
radiotherapy
refractory lymphoma
relapsed lymphoma
Risk factors
secondary cancer prevention
secondary cancers
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
Tuberculosis
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe